SEARCH

SEARCH BY CITATION

References

  • 1
    Dienstag JL, McHutchison JG, et al. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006; 130: 23164.
  • 2
    World Health Organization. Hepatitis C. World Health Organization, Geneva, Switzerland 2000 October. Available at http:www.who.int/mediacentre/factsheets/fs165/en. Accessed: August 15, 2012.
  • 3
    El-Serag HB, Mason AC, et al. Rising incidence of heaptocellular carcinoma in the United States. New Eng J Med 1999; 340: 74550.
  • 4
    Kim WR. The burden of Hepatitis C in the United States. Hepatology 2002; 36(Suppl): S304.
  • 5
    Ghany MG, Strader DB, Thomas DL, et al. AASLD Practice Guidelines: diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 133575.
  • 6
    Jacobson IM. Treatment options for patients with chronic hepatitis C not responding to antiviral therapy. Clin Gastroenterol Hepatol 2009; 7: 921–30.
  • 7
    Lohmann V, Körner F, Koch J, et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 1103.
  • 8
    Lindenbach BD, Evans MJ, Syder AJ, et al. Complete replication of hepatitis C virus in cell culture. Science 2005; 309: 6236.
  • 9
    Pawlotsky JM. The hepatitis C viral life cycle as a target for new antiviral therapies. Gastroenterology 2007; 132: 197998.
  • 10
    Reesink HW. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase 1b, placebo-controlled, randomized study. Gastroenterology 2006; 131: 9971002.
  • 11
    Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis c virus replication in patients. Hepatology 2007; 46: 6319.
  • 12
    Forestier N, Reesink HW, Weegink CJ, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007; 46: 6407.
  • 13
    Lawitz E, Rodriguez-Torres M, Muir AJ, et al. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol 2008; 49: 1639.
  • 14
    McHutchinson JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. New Eng J Med 2009; 360: 182738.
  • 15
    Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. New Eng J Med 2009; 360: 183950.
  • 16
    McHutchinson JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. New Eng J Med 2010; 14: 1292303.
  • 17
    Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. New Eng J Med 2011; 364: 240516.
  • 18
    Kieffer TL, Bartels G, Sullivan J. , et al. Clinical Virology Results from Telaprevir Phase 3 Study ADVANCE. Hepatology 2010; 52(Suppl.): 223A.
  • 19
    Sherman KE, Flamm SL, Afdhal NH, et al. Telaprevir in combination with peginterferon alfa2a and ribavirin for 24 or 48 weeks in treatment-naïve genotype 1 HCV patients who achieved an extended rapid viral response: final results of phase 3 ILLUMINATE study. Hepatology 2010; 52(Suppl.): 401A.
  • 20
    Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. New Eng J Med 2011; 364: 241728.
  • 21
    Foster GR, Zeuzem S, Andreone P, et al. Subanalyses of the telaprevir lead-in arm in the REALIZE study: response at week 4 is not a substitute for prior null response categorization. J Hepatol 2011; 54(Suppl. 1): S34.
  • 22
    Zeuzem S, Sulkowski MS, Zoulim F, et al. Long-term Follow-up of Patients with Chronic Hepatitis C Treated with Telaprevir in Combination with Peginterferon Alfa-2a and Ribavirin: Interim Analysis of the EXTEND Study. 61st Annual Meeting of the American Association for the Study of Liver Diseases. Hepatology 2010; 52(Suppl.): 436A.
  • 23
    Muir AJ, Poordad FF, McHutchison JG, et al. Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology 2011; 54: 153846.
  • 24
    Sulkowski MS, Roberts S, Afdhal NH, et al. Ribavirin dose modification in treatment-naïve and previously treated patients who received telaprevir combination treatment: no impact on sustained virologic response in phase 3 studies. J Hepatol 2012; 56(Suppl.): S459–60.
  • 25
    Hezode C, Dorival C, Zoulim F, Poynard T, et al. Safety of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in cirrhotic nonresponders. First results of the French early access program (ANRS CO20-CUPIC). J Hepatol 2012; 56(Suppl.): S4.
  • 26
    Marcellin P, Forns X, Goeser T, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology 2011; 140: 45968.
  • 27
    Dieterich D, Soriano V, Sherman K, et al. Telaprevir in combination with pegylated interferon-alfa-2a 1 ribavirin in HCV/HIV-coinfected patients: a 24-week treatment interim analysis. Presented at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012). 2012. Available at http://retroconference.org/2012b/Abstracts/42969.htm.
  • 28
    Foster GR, Hézode C, Bronowicki JP, et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011; 141: 8819.
  • 29
    Incivek (package insert). Cambridge, Mass: Vertex Pharmaceuticals, 2011. Available at http://www.incivek.com/. Accessed November 12, 2012.
  • 30
    Jacobson IM, Bartels DJ, Gritz L, et al. Futility rules in telaprevir combination treatment. J Hepatol 2012; 56(Suppl.): S24.